BN Business News
Add your company to Business Communicator →

Business · 04/11/20261 min read

Opinion/decision on a PIP: Uplizna, inebilizumab, type of decision: PM: decision on the application for modification of an agreed PIP, area of treatment: Musculoskeletal and connective tissue disorders, number of PIP: EMA/PE/0000252649

Summary

Opinion/decision on a PIP: Uplizna, inebilizumab, type of decision: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective...

Original source language: EMA — Paediatric Investigation PlansOpen original release →

Explore insights

Business insights →